| abstract |
A therapeutic combination comprising a therapeutically effective amount of a compound chosen from 4- (2- (1H-indazol-4-yl) -6 - ((4- (methylsulfonyl) piperazin-1-yl) methyl) thieno [3, 2-d] pyrimidin-4-yl) morpholine, which has the formula Ia: ** Formula ** (S) -1- (4 - ((2- (2-aminopyrimidin-5-yl) -7-methyl- 4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-hydroxypropan-1-one, which has the formula Ib ** Formula ** and stereoisomers, geometric isomers, tautomers , or pharmaceutically acceptable salts thereof; and a therapeutically effective amount of a chemotherapeutic agent chosen from erlotinib, docetaxel, 5-FU, gemcitabine, PD-0325901, cisplatin, carboplatin, paclitaxel, bevacizumab, trastuzumab, pertuzumab, temozolomide, tamoxifen, doxorubicin, Akti-1/2 , rapamycin, and lapatinib; wherein the therapeutic combination has an IQ score (combination index) of less than 0.8 in a tumor cell line, the IC score being calculated by the Chou and Talalay method from the EC50 values obtained in an in vitro cell proliferation assay and the type of tumor being chosen among breast, cervical, colon, endometrial, glioma, lung, melanoma, ovarian, pancreatic and prostate tumors. |